Understanding MUC5B and Lung Scarring
Endoplasmic reticulum stress in MUC5B-driven lung fibrosis
This project explores how a specific gene, MUC5B, and cellular stress contribute to the development of lung scarring, also known as Idiopathic Pulmonary Fibrosis.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-11132863 on NIH RePORTER |
What this research studies
Our bodies have a gene called MUC5B, and a specific change in this gene is a major factor for developing a serious lung condition called Idiopathic Pulmonary Fibrosis (IPF). In people with IPF, this MUC5B gene is overly active in certain lung cells. We are working to understand exactly how too much MUC5B in the small airways leads to lung scarring. We believe that stress within lung cells, called endoplasmic reticulum stress, plays a key role in this process. By uncovering these connections, we hope to find new ways to help patients with IPF.
Who could benefit from this research
Good fit: This research is relevant for individuals with Idiopathic Pulmonary Fibrosis (IPF), especially those with the MUC5B gene variant, or those at risk of developing the condition.
Not a fit: Patients whose lung fibrosis is not related to MUC5B gene activity or endoplasmic reticulum stress may not directly benefit from this specific line of research.
Why it matters
Potential benefit: If successful, this work could lead to new treatments that target the MUC5B gene or cellular stress pathways to prevent or slow the progression of lung fibrosis.
How similar studies have performed: Previous findings have established the MUC5B gene variant as a dominant risk factor for IPF, and other studies link ER stress to lung fibrosis, suggesting a strong foundation for this approach.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Schwartz, David Albert — University of Colorado Denver
- Study coordinator: Schwartz, David Albert
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.